Compare FT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FT | CRVS |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.0M | 843.7M |
| IPO Year | N/A | 2016 |
| Metric | FT | CRVS |
|---|---|---|
| Price | $7.27 | $10.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 48.3K | ★ 831.6K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 7.85% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.95 | $6.39 |
| 52 Week High | $8.35 | $26.95 |
| Indicator | FT | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 43.54 |
| Support Level | $6.95 | $9.40 |
| Resistance Level | $8.32 | $10.81 |
| Average True Range (ATR) | 0.10 | 0.72 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 20.00 | 21.82 |
Franklin Universal Trust is a closed-end management investment company whose primary investment objective is to provide high current income consistent with preservation of capital. Its secondary objective is growth of income through dividend increases and capital appreciation. The company invests mainly in two asset classes: high-yield bonds and utility stocks. Its high-yield bond portfolio consists of a diversified portfolio of bonds selected through fundamental research, while its utility stock portfolio focuses on companies with attractive dividend yields and a history of increasing their dividends.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.